Drugs / Manganese Chloride
Manganese Chloride
Regulatory milestones approvals, filings & regulatory actions · 1 recorded
| Milestone | Jurisdiction | Brand | Indication | Date | Sentence it was read from |
|---|---|---|---|---|---|
| Approved | US (FDA) | MANGANESE CHLORIDE IN PLASTIC CONTAINER | — | 1986-06-26 | fda.gov ↗ |
Trials 7 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/24 trials | ||||||
| Phase 1/2 | NCT05451654 | Feb → Oct 2022 | COVID-19 | Medesis Pharma SA | Terminated | No outcome recorded |
| Phase 1/2 | NCT04873440 | May 2021 → May 2022 | lymphoma | Chinese PLA General Hospital | Unknown | No outcome recorded |
| Phase 1/2 | NCT03989310 | Mar 2019 → May 2021 | malignant pancreatic neoplasm | Chinese PLA General Hospital | Unknown | No outcome recorded |
| Phase 1/2 | NCT04004234 | Mar 2019 → Aug 2020 | biliary tract cancer | Chinese PLA General Hospital | Unknown | No outcome recorded |
| Phase 22 trials | ||||||
| Phase 2 | NCT03989336 | Dec 2020 → May 2022 | ovarian cancer | Chinese PLA General Hospital | Completed | No outcome recorded |
| Phase 2 | NCT00963131 | Dec 2004 → Dec 2008 | central serous chorioretinopathy | Prince of Songkla University | Completed | No outcome recorded |
| Phase 31 trial | ||||||
| Phase 3 | NCT04119843 | Feb 2020 → Feb 2023 | liver and intrahepatic bile duct neoplasm | Ascelia Pharma AB | Completed | No outcome recorded |
Also used as a comparator or background therapy in 1 trial
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT03991559 Comparator | Nov 2018 → Dec 2019 | cancer, lymphoma | Chinese PLA General Hospital | Unknown | No outcome recorded |
Evidence & citations 9 cited values
Every value below carries the sentence it was read from. 8 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Manganese Chloride | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04004234 ↗ |
| Known as | manganese | “manganese 4 mg” NCT00963131 ↗ |
| Known as | Manganese sulfate monohydrate | “Manganese sulfate monohydrate, MnSO4, H2O (NanoManganese®) will be administered using the microemulsion AONYS® technology.” NCT05451654 ↗ |
| Known as | Mangoral | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04119843 ↗ |
| Known as | MnSO4, H2O | “Manganese sulfate monohydrate, MnSO4, H2O (NanoManganese®) will be administered using the microemulsion AONYS® technology.” NCT05451654 ↗ |
| Known as | NanoManganese | “Manganese sulfate monohydrate, MnSO4, H2O (NanoManganese®) will be administered using the microemulsion AONYS® technology.” NCT05451654 ↗ |
| Action | Activate | “Manganese has been confirmed to activate antigen-presenting cells” NCT04004234 ↗ |
| Modality | Other / unclassified | “function as mucosal immunoadjuvants” NCT04004234 ↗ |
| Route | Inhaled | “Administered by inhalation” NCT03989310 ↗ |